Age-Related Macular Degeneration (ARMD) Treatments

Find Age-Related Macular Degeneration (ARMD) Treatments

Generic Name

Ranibizumab

Brand Names

Byooviz, Cimerli, Lucentis, Nufymco, Susvimo

FDA approval date: June 30, 2006

Classification: Vascular Endothelial Growth Factor Inhibitor

Form: Injection

What is Byooviz (Ranibizumab)?

BYOOVIZ is indicated for the treatment of patients with: BYOOVIZ, a vascular endothelial growth factor inhibitor, is indicated for the treatment of patients with: Neovascular Age-Related Macular Degeneration .

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)

Who is this study for: Patients with neovascular age-related macular degeneration previously treated with intravitreal agents other than ranibizumab

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Device, Drug

Study Drug: Lucentis

Study Phase: Phase 4

Summary: This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

A Phase III, Multicenter, Randomized, Visual Assessor-masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Chinese Patients With Neovascular Age-related Macular Degeneration

Enrollment Status: Recruiting

Publish Date: June 08, 2026

Intervention Type: Device, Drug

Study Phase: Phase 3

Summary: This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in Chinese participants with nAMD.

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)

Who is this study for: Patients with Neovascular Age-Related Macular Degeneration

Enrollment Status: Recruiting

Publish Date: June 04, 2026

Intervention Type: Drug

Study Drug: PDS Implant with Ranibizumab

Study Phase: Phase 3

Summary: This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to ...

View All Clinical Trials